News coverage about Charles River Laboratories (NYSE:CRL) has trended somewhat positive on Wednesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Charles River Laboratories earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 47.0083592417782 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
CRL has been the topic of a number of research reports. Barclays reiterated a “hold” rating and set a $110.00 price target on shares of Charles River Laboratories in a research report on Friday, February 16th. Credit Suisse Group reiterated a “hold” rating and set a $108.00 price target on shares of Charles River Laboratories in a research report on Thursday, February 15th. Morgan Stanley reiterated an “equal weight” rating and set a $102.00 price target (up from $94.00) on shares of Charles River Laboratories in a research report on Wednesday, March 14th. Robert W. Baird set a $123.00 price target on Charles River Laboratories and gave the stock a “buy” rating in a research report on Tuesday, February 13th. Finally, SunTrust Banks cut Charles River Laboratories from a “buy” rating to a “hold” rating and increased their price target for the stock from $107.89 to $111.00 in a research report on Monday, January 22nd. They noted that the move was a valuation call. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Charles River Laboratories presently has an average rating of “Buy” and a consensus price target of $116.85.
CRL opened at $108.01 on Wednesday. Charles River Laboratories has a 12 month low of $86.66 and a 12 month high of $119.05. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.54 and a current ratio of 1.78. The company has a market capitalization of $5,029.84, a P/E ratio of 20.50, a price-to-earnings-growth ratio of 1.59 and a beta of 0.68.
Charles River Laboratories (NYSE:CRL) last posted its earnings results on Tuesday, February 13th. The medical research company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.26 by $0.14. Charles River Laboratories had a return on equity of 26.14% and a net margin of 6.64%. The firm had revenue of $478.50 million for the quarter, compared to analysts’ expectations of $475.02 million. During the same period last year, the firm earned $1.21 EPS. The firm’s revenue was up 2.5% compared to the same quarter last year. research analysts expect that Charles River Laboratories will post 5.77 earnings per share for the current fiscal year.
In related news, Director George M. Milne, Jr. sold 7,740 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $115.00, for a total value of $890,100.00. Following the sale, the director now directly owns 36,760 shares in the company, valued at approximately $4,227,400. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Online Communications Bdirect sold 131,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $0.29, for a total value of $37,990.00. Over the last 90 days, insiders sold 193,658 shares of company stock worth $6,913,383. 2.10% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/18/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-charles-river-laboratories-crl-stock-price.html.
About Charles River Laboratories
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Receive News & Ratings for Charles River Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.